GENE-THERAPY OF HUMAN-MELANOMA - IMMUNIZATION OF PATIENTS WITH AUTOLOGOUS TUMOR-CELLS ADMIXED WITH ALLOGENEIC MELANOMA-CELLS SECRETING INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR

To actively immunize HLA-A1 and/or HLA-A2 positive patients with irrad iated autologous tumor cells admired with HLA-A 1,A2 positive allogene ic melanoma cells that have been genetically modified by transfection to secrete interleukin 6 (IL-6) and soluble IL-6 receptor (sIL-6R). 1. To evaluate local and systemic toxicity of multiple subcutaneous (s.c .) injections of the mixture of autologous and IL-6/sIL-6R-producing a llogeneic tumor cells. 2. To evaluate the induction or augmentation of tumor-specific and nonspecific immune responses. 3. To assess potenti al anti-tumor effects of the treatment.